Abstract: Planar chip technology has strongly facilitated the progress towards fully automated electrophysiological systems that, in contrast to the traditional patch clamp technology, have the capability of parallel compound testing. The throughput has been increased from testing below 10 compounds per day to a realized capacity approaching high throughput levels. Many pharmaceutical companies have implemented automated planar chip electrophysiology in their drug discovery process, particularly at the levels of lead optimization, secondary screening and safety testing, whereas primary screening is generally not performed. In this review, we briefly discuss the technology and give examples from selected NeuroSearch ion channel programs, where one of the systems, the QPatch, has been evaluated for use in lead optimization and primary screening campaigns, where high information content was a requirement.
INTRODUCTION

Ion Channels and Electrophysiology
Ion channels are membrane spanning proteins, which allow a gated, selective flow of small inorganic ions across biological membranes. Ion channels participate in diverse physiological processes, such as the electrical and chemical signaling in excitable cells, the control of cell division and migration of proliferative cells, as well as bulk transport of salt across epithelia and endothelia. Ion channels also participate in numerous pathological conditions, and mutations in ion channel genes may itself lead to ion channel diseases, so called channelopathies [1] . The pharmaceutical industry has an interest in the pharmacology of ion channels since these potentially represent attractive new drug targets, but also because drug interaction with specific ion channels may produce unacceptable off-target effects. Ion channels are, however, particularly difficult targets for drug discovery, deviating considerably from enzymes and 7-TM receptors: The process of gating imposes an all-or-none behavior on ion channels, which is fundamental for the tuning of an ion channel population to generate a particular physiological response, such as initiating and ending an action potential within a millisecond. Thus, tightly controlled (time, voltage) high resolution recordings are often an absolute requirement in order to detect the relevant drug interaction with an ion channel. Classic drug discovery disciplines like receptor binding, measurement of radioactive fluxes, and even fluorescent based measurements of ion fluxes or changes in membrane potentials, do therefore often not suffice.
Since the description of the improved patch clamp technique [2] , this technology has been viewed as the standard for characterizing the biophysics and pharmacology of ion channels: Via an electrically and mechanically tight coupling of the tip of a glass pipette ( ~ 1 M) to the cell membrane, *Address correspondence to this author at the NeuroSearch A/S, Pederstrupvej 93, DK 2750 Ballerup, Denmark; Tel: +45 44 60 82 22; Fax: +45 44 60 80 00; E-mail: pc@neurosearch.dk measurements of small ion channel currents is possible in both whole-cell and excised patches. However, the patch clamp technique is quite laborious and has never achieved widespread popularity or use as a screening method in the pharmaceutical industry. As a consequence, ion channel drug discovery programs may have been abandoned due to the limited capacity for electrophysiological validation of hit substances. Thus, there has long been an urge towards making the electrophysiology more efficient and easier to perform by making the process automatic and parallel.
Patch Clamp Automation
The automation of patch clamp electrophysiology has been a gradual process reviewed in detail by Mathes [3] . A major step was the development of the EPC-9 [4, 5] , which was the first traditional patch clamp amplifier being 100% computer controlled, with integrated data acquisition, extended automatic compensation routines and online analysis capabilities. Thus the EPC-9 was the natural platform for several 1. generation attempts towards full automation based on the classical patch clamp technology, such as the NeuroPatch/Apatchi [6] and Autopatch systems, and updated versions remain even today the amplifier of choice in the Port-aPatch/Patchliner systems.
A very significant progress towards higher throughput electrophysiology was the re-thinking of the "rendezvous" between the cell and the measuring device. In traditional patch clamp the tip of the glass pipette is brought to the cell surface, but with the chip based solutions the cell is brought to the hole of a perforated planar substrate [7, 8] . Whereas every cell chosen for patch clamp experiments is manually selected based upon its appearance in the microscope, a cell suspension is applied blindly for attachment in the chip based systems. This made the process suitable for automation and parallelization, but also imposed an increased demand on cell quality and homogeneity of the cell suspension.
Commercial chip-based systems for automated and parallel electrophysiological recordings are now in practical use in the pharmaceutical industry. The 1 QPatch, 2 Port-a-Patch/Patchliner, PatchExpress and 3 IonWorks HT systems use single cell electrophysiology aiming at medium throughput screening/ characterization with near complete preservation of the high quality of the classic patch clamp technique. IonWorks HT also offers cell population based electrophysiology approaching the level of genuine high-throughput screening, although on the expense of electrophysiological fidelity and flexibility.
The automatic patch clamp systems are now considered so mature in terms of throughput, stability and analysis capabilities, that it is feasible to discuss their roles, not only in drug characterization/secondary screening, but also in primary screening programs, where the high information content of the drug/channel interaction is considered the primary output and thereby justifies the higher cost as compared to traditional assays like the FLIPR (fluorometric imaging plate reader).
In this paper we present three case stories on the use of automated planar electrophysiology: (I) Establishment of an assay for detection of state-dependent Na + channel inhibitors; (II) Establishment of an assay for identification of positive and negative gating modulators of K Ca 2 (a.k.a. SK) channels; and (III) Report from an ongoing screening campaign for identification of positive modulators of K v 11.1 (a.k.a. hERG) channels. Each case story is initiated with a short monograph on the ion channels in question.
The QPatch System
The work described was conducted with QPatch systems. The QPatch comes as a 16-and as a 48 channel version (QPatch HT) based on the same basic principle; parallel whole-cell recordings with independent voltage-and suctioncontrol as well as compound addition. In short, the planar substrate (or chip) where the whole-cell configuration is established is embedded in a single-use device, the QPlate, which also contains the electrodes and the flow channels to deliver intra-and extracellular solutions. Both QPatch systems stack the disposable QPlates and the HT-system also stacks up to twenty 96-well format compound plates. Cells for the experiments are prepared by a centrifugation/wash procedure from a stirred cell suspension placed on the platform. All liquid handling, including cell transfer, cell wash and compound delivery, is done by the integrated pipette robot (4 or 8 pipettes). This means that cells, QPlates and compound plates are placed on the platform according to the prepared assay and no operator intervention is needed after initiation of the job. The whole-cell recordings are based on high resistance seals (G ) and employ series resistance compensation as defined by the operator. Applications of compounds are carried out during data acquisition, which enables analysis of time-courses before and during drug application. This allows correction for run-down/run-up (see later) as well as extraction of the kinetics of channel-drug interaction, just as in standard patch clamp experiments. The upstroke of the neuronal as well as the cardiac action potentials is carried by Na + ions flowing through voltagegated Na + channels (Na v channels) activated by a membrane depolarization. The steady-state voltage-dependence is steep with only 40 mV difference between no and full activation. Even more striking is the kinetics of the activation and of the subsequent inactivation of the channel, which both occur with time constants of less than 1 ms. After repolarization of the membrane, the return of the channel to a resting closed state, from which it can be re-activated, is a slower process, lasting 10-100 th of ms. This is a physiologically important feature that ensures unidirectional spreading of action potentials, but it is also the biophysical process that is strongly delayed by use-dependent blockers (see later).
Na v channels are clustered in a family with 9 members with continuous polypeptides of around 2000 amino acids constituting the functional pore-forming -subunits. This makes Na v channels a challenge to clone and express in heterologous systems, but despite that, stable clones of all subtypes of Na + channels are now available and suitable for biophysical and pharmacological characterization. Na v channel drugs have long been utilized clinically. Local anesthetics like procaine have been known for more than 100 years, but many Na v -acting drugs, if not all, were not recognized as such prior to entrance into the clinical market. This knowledge arose only gradually from electrophysiological studies of neurons, and were in particular accelerated and refined by patch clamp analyses of cloned Na v channels. This reverse pharmacological engineering has high-lighted the voltageand state-dependent mode of action (MOA) of the clinical Na v channel blockers, as well as the binding site for these compounds [9] . State-dependent blockers preferentially act on pathophysiological events like sustained depolarizations and repetitive firing that occur e.g., during ischemia and under epileptic discharges, leaving the physiologically activated channels essentially unaltered. This renders them safe drugs in the treatment of diseases like pain, epilepsy and cardiac arrhythmia. The "use-dependency" contrasts with the specific and potent "tonic" block, exerted by pore-blockers like tetrodotoxin (TTX), which is lethal due to block of the Na v channels irrespective of their physiological setting. In general, despite the fact that Na v channels are differentially distributed between tissues and even between cellular compartments (i.e. Na v 1.2 being axonal and the other brain types being somato-dendritic [10] ), state-dependency rather than subtype selectivity has long been considered most important in the achievement of an acceptable therapeutic index. This notion was accentuated by the recognition of how functionally as well as structurally homologous the Na v channel subtypes are: Na v 1.1, 1.2, 1.3, 1.4, 1.6 and 1.7 share more than 90% sequence identity [11] , and the core local anesthetic site is preserved among all subtypes. Despite the well known categorization of Na v channels in TTX-sensitive (subtypes 1. In the evaluation of the QPatch system for screening for Na v inhibitors, we first compared its capability for biophysical characterization of Na v channels with manual patch clamp. Next, the basic performance with respect to pharmacological characterization was evaluated, and finally a test protocol was defined that allows a simple read-out for statedependent inhibition.
Two different rat Na v subtypes were employed in the evaluation, the TTX-sensitive subtype Na v 1.2a, which is the dominant brain subtype, and Na v 1.5a, a splice variant of the TTX-insensitive cardiac subtype. Na v 1.5a lacks 53 continuous amino acids in the intracellular loop between domain II and III. It was cloned from a neuronal stem cell progenitor derived from rat hippocampus [13] and is also expressed in intact brain tissue. Apart from being differentially sensitive towards TTX, these channels also differ in their biophysics of activation and inactivation, hence also in their susceptibility towards state-dependent block. Fig. (1) shows representative current traces (left panels) as well as average peak current voltage (IV) curves (right panels) for the two subtypes. The kinetics of activation and inactivation was significantly slower for Na v 1.5a than for Na v 1.2a in accordance with previous experiments [14] . For both channels a gradual increase in both activation and inactivation rates is obtained with increasing depolarization, resulting in an earlier peak current. The I-V curves show the difference in steady-state voltage-dependency with the threshold for activation of Na v 1.5a being approximately 20 mV more negative than for Na v 1.2, in line with manual patch clamp results [13, 15] . For both channels, the peak-currents gradually increased during the range of negative potentials where the channels become more and more activated and then gradually decreased at the positive potentials where Na v channels are fully activated, but where the driving force on the Na + ion decreases. In conclusion, the overall biophysical activation/inactivation kinetics by the two channels is faithfully reported by the QPatch system, indicating that possible system specific concerns is not prohibitive for performance of high-quality voltage clamp studies. It is important to stress, however, that QPatch recordings are sensitive to all known confounding factors known from manual patch clamp, such as large currents, large cells, imperfect cell geometries, high series resistance, etc.
The TTX-sensitivities were measured on the two subtypes as shown in Fig. (2) . The channels were activated by recurrent voltage steps to 0 mV and increasing concentrations of TTX were added accumulatively to the cells. As expected, the activation/inactivating kinetics of the currents were unchanged by TTX (see traces in Fig. 2A) . The peak currents have been plotted versus the concentration of TTX (Fig. 2B) and a Hill-fit revealed IC 50 values of 11 nM and 1.0 M for Na v 1.2a respectively Na v 1.5a (the corresponding values from manual patch clamp were 9 nM and 0.9 M, data not shown). In conclusion, the overall performance of the QPatch compound handling, application system, and solution exchange on the chip allow basic pharmacological experiments to be reliably performed. Importantly, however, just as with normal patch clamp experiments, compounds with slow drug-receptor kinetics, may need long incubation times to yield genuine concentration response curves. 3) shows recovery from inactivation experiments performed with Na v 1.2a: After full inactivation by a step to 0 mV for 100 ms, the channels were allowed to recover from inactivation at -90 mV for a variable period of time before a new step to 0 mV was performed. Fig. (3A) shows the recovery of the second peak in the control situation as well as in the presence of lidocaine. Fig. (3B) shows the relative current amplitude from the second step versus the recovery time. The time course of recovery from inactivation occurred, in accordance with the literature, in two phases; a fast ( fast = 2.5 ms) as well as a slow ( slow = 279 ms) with a fraction of fast recovery of 79%. Application of lidocaine, a prototype state-dependent Na v channel blocker, greatly prolonged the time to full recovery, apparently by selectively increasing the fraction of channels recovering slowly leaving the fast fraction at 29%.
Further evaluation of this double pulse paradigm for screening for state dependency led finally to a double pulse protocol with a first depolarizing pulse of 100 ms length with 15 ms repolarization at -90 mV for recovery. Fig. (4) shows an experiment where TTX and lidocaine were added to the same cell. Whereas the tonic blocker TTX exerted proportionally equal block on both peaks lidocaine only blocked the current elicited by pulse 2 leaving the pulse 1 current unaltered. This protocol proved efficient in the screening for state-dependency not only of the type exerted by lidocaine but also picked up a large number of antiepileptic and neuroprotective drugs, such as lamotrigine, sipatrigine, lubeluzole, riluzole, but notably not crobenetine (data not shown).
Small Conductance Ca
2+ -Activated K + Channels
Small conductance Ca 2+ -activated K + channels (K Ca 2, SK) are important regulators of neuronal excitability and timing of action potentials, and K Ca 2 channels expressed in peripheral non-excitable cells participate in membrane potential regulation [16, 17] . SK Ca 2 channels constitute of family of three highly homologous channels, K Ca 2.1-2.3 (SK1-SK3) that are gated by the intracellular [Ca 2+ ] i via calmodulin constitutively bound to the C-termini of the four subunits. Experiments with excised patches that allow tight The average (n = 9) of the relative current amplitude of peak 2 as a function of the repolarization time ( t) for control ( ) and in the presence of 300 M lidocaine ( ). The solid curves represent fits of the data to a biexponential function with the sum of the two fractions locked in unity. This gave time constants for the fast and slow recovery of (control) fast = 2.5 and slow = 279 ms with 79% in the fast fraction. . From a holding potential of -90 mV the following pulse protocol was elicited every 10 s; a first 100 ms step (truncated to 5 ms on the figure) to 0 mV was applied, followed by a 15 ms repolarization at -90 mV, before a second 10 ms step to 0 mV was imposed. The tonic TTX block affected either peak identically, whereas the state-dependent effect of lidocaine was noted as an unaltered first peak, while the second peak was diminished. (B) A plot of the peak currents elicited from the first ( ) and second ( ) pulses versus time. The presence of TTX and lidocaine is indicated by the horizontal bars.
No drugs have K Ca 2 channels as the primary target although several interact with K Ca 2 channels, e.g., the activator riluzole [22] and the blocker fluoxetine [23] . However, modulation of K Ca 2 channels may be a therapeutic principle for intervention in Parkinson disease, depression, schizophrenia, myotonic muscular dystrophy, cerebellar ataxia, migraine, anorexia nervosa, and urinary incontinence (for a review see [17] ). K Ca 2 channels are specifically and potently blocked by the peptide apamin that blocks the pore from the outside. Other venom peptides as well as certain positively charged organic compounds inhibit the channels by a similar mechanism and displace apamin in binding experiments [24, 25] . While these pore blockers are excellent tools in the in vitro elucidation of K Ca 2 channel impacts on physiological processes, their physicochemical properties limit their use for in vivo studies and they are probably not drug candidates either. ] 0.5 value may become less than 100 nM [20] . Recently, the first negative gating modulator of K Ca 2 channels, NS8593, was described. In contrast to the blockers, NS8593 does not displace apamin, but decreases the Ca 2+ -sensitivity and in the presence of 3 M NS8593 [Ca 2+ ] 0.5 is increased to 1.6 M [25] .
In order to detect compounds with either mode of action (MOA), the [Ca 2+ ] i must be controlled in a narrow band of 300-700 nM, corresponding to 14-80% of maximal activation by Ca 2+ [20] : Obviously, the effect of both pore blockers and negative gating modifiers requires that the channels are activated and, on the other hand, neither positive nor negative modulators have any effect on fully activated channels (in contrast to pore blockers). However, the resting [ Ca   2+ ] i of e.g., HEK293 or CHO cells is low, probably below 100 nM, which excludes direct detection of inhibitors and furthermore only detects positive modulators that shift the Ca 2+ activation curve prominently. Experimental activation of the channels by application of a positive modulator [27] or by elevation of [Ca 2+ ] i is therefore necessary when screening on intact cells measuring Rb + flux (atomic absorption), Tl + flux or membrane potential changes (fluorescence) and in nystatin/amphotericin perforated patches (electrophysiology). In principle, however, full characterization of compounds that modify K Ca 2 channel activity requires studies in the inside-out configuration, where the [Ca 2+ ] can be controlled and varied during the experiment. Unfortunately such measurements are time-demanding, require skilled electrophysiologists, and are not yet amenable to any high throughput format. The second best is, in our experience, to perform traditional whole-cell experiments using an intracellular saline (IS) with a tightly buffered [Ca 2+ ]. This allows partial control of the K Ca 2 channel activity, which can be kept relatively stable over time. A particularly nice opportunity is probably the Port-a-Patch system, which allows exchange of the intracellular saline during the experiment.
Establishment of a K Ca 2.3 Channel Assay for Compounds with Different MOAs
Our work in the field of K Ca 2 modulators has lead to the identification of pore blockers as well as negative and positive gating modulators. Although primary hits for the various categories were initially identified by FLIPR technology, we addressed whether the QPatch had the potential of being a more general platform for the lead optimization of K Ca 2 compounds comprising different MOAs.
All studies were performed with the human isoform of K Ca 2.3 expressed in HEK293 cells. Partial K Ca 2 channel activation was achieved by an intermediate [Ca 2+ ] i and an increased Ca 2+ -sensitivity induced by positive modulators is therefore reflected in an increase in current, whereas a decreased Ca 2+ -sensitivity or a pore block are measured as a decrease in current. Experiments were performed using a physiological [K + ] gradient across the cell membrane and currents were elicited by a linear voltage ramp (-120 mV to +30 mV). Under these conditions a K + -selective current reverses at -90 mV and a possible leak current can therefore be estimated at this potential. The gating of K Ca 2 channels is independent of voltage, but since the pore is blocked voltage-dependently by intracellular Mg 2+ , the slightly rectifying IV curves were used as a signature for K Ca 2 currents. This is illustrated in Fig. (5A) that shows current traces obtained from voltage ramps applied in an experiment with [Ca 2+ ] IS buffered at 300 nM. A significant K Ca 2.3 current (600 pA at 0 mV) is detectable in the control trace recorded 7 min after establishment of the whole-cell configuration and application of increasing concentrations of the positive modulator NS309 induced discrete increases compared to this control current. Similar experiments were performed with varying [Ca 2+ ] IS and the time-courses of three experiments are depicted in Fig. (5B) . In the experiments with 300 nM and 3 M Ca 2+ the K Ca 2.3 current increased gradually after breakthrough to whole-cell configuration due to equilibration with the higher [Ca 2+ ] IS , whereas that was not the case with 100 nM free Ca
2+
. NS309 concentration-dependently activated the K Ca 2.3 current to the same maximal current level at all [Ca 2+ ] IS irrespective of the level of control current. As shown in Fig. (5C) It is notable, that these NS309 concentration-responses are the first to be performed using the whole-cell configuration, at least in our laboratory, since in conventional wholecell patch clamp experiments we inevitably loose the cells at high degrees of channel activation. Thus the demonstration of the EC 50 value dependency on [Ca 2+ ] i was enabled by the QPatch experiments. Furthermore, a gradual loss of rectification was observed at higher NS309 concentrations (Fig. 5A) . These findings may well hint towards important, and as yet unresolved, mechanistic interactions between positive modulators and K Ca 2 channels.
The assay conditions described above were also usable for pore blockers and even negative modulators, due to the intermediate degree of activation of the channels. Fig. (6A) shows the time course of a concentration-response experiment using the negative gating modulator NS8593. The broken line represents the estimated run-up of the control current during the period of NS8593 application and was used for calculation of the degree of K Ca 2.3 current inhibition. The average concentration-response plots for NS8593 as well as for the pore blockers apamin, UCL1684 and bicuculline methobromide are shown in Fig. (6B) . The IC 50 values obtained from a Hill-fit to the QPatch data were in nice agreement with manual whole-cell patch clamp data as illustrated in Fig. (6C) that also includes data on 7 other negative modulators. The IC 50 value of 187 nM found in this study compares well with the whole-cell value of 90 nM published previously [25] . Given that the potency of NS8593 decreases from 0.47 M to 14 M when [Ca 2+ ] i is increased from 300 nM to 10 M in inside-out patches [25] the [Ca 2+ ] i in the vicinity of the channels were considerably lower than 300 nM. ] IS . The HEK293 cell line stably expressing hK Ca 2.3 channels was cultured in T175 flasks with standard growth medium at 37°C and 5% CO 2 . The cells were harvested by trypsin or detachin treatment, suspended in serum free medium, and adjusted to a cell density of 3-5•10 6 /mL before they were transferred to the stirrer on the QPatch platform. After a typical residence time of 15-45 min the first experiment was initiated. The extracellular saline consisted of (in mM): 144 NaCl, 4 KCl, 2 CaCl 2 , 1 MgCl 2 and 10 HEPES, pH 7.4 with NaOH. After establishment of the wholecell configuration a modified extracellular saline with 0.1 mM CaCl 2 and 3 mM MgCl 2 was used. The ISs all contained 154 mM KCl and 10 mM HEPES as well as 10 mM of a Ca 2+ chelator (EGTA or a combination of EGTA and NTA). CaCl 2 and MgCl 2 were added to give the specified free concentration of Ca 2+ and 1 mM free Mg . The closed symbols indicate the currents measured before the first application of NS309 and under these control conditions the relative degree of activation was 1.4 ± 0.37% (n = 2) in 100 nM; 5.1 ± 0.7% (n = 3) in 300 nM; 38 ± 5% (n = 3) in 400 nM; and 37 ± 7.6% (n = 3) in 3 M Ca ] IS . The observation is equivalent to observations from manual patch clamp and may be due to strongly competing cellular Ca 2+ buffering (or transport) mechanisms. However, this is not prohibitive for obtaining intermediate channel activation and hence we conclude that the QPatch system provides the basic electrophysiological qualities required for a lead optimization program on K Ca 2 channels irrespective of the desired MOA.
K v 11.1 Channels
hERG (human ether-à-go-go-related gene) encodes the ion channel K v 11.1 that mediates the rapid delayed rectifier potassium current known as I(K r ) in the heart. In contrast to the slow delayed rectifier (I(K s ) which is carried through K v 7.1/minK channels) and ultra rapid potassium conductance (I(K ur ) which is carried through K v 1.5 channels), the kinetics of the K v 11.1 channel is characterized by fast activation with even faster inactivation occurring simultaneously resulting in only a small current during the plateau phase of the cardiac action potential [28] . In the re-polarizing phase, however, the channel transition from the inactivated to the closed state goes via the open channel state followed by deactivation to the closed channel, and this gives rise to a transient outward current. Together with K v 7.1/minK the K v 11.1 channel constitute most of the repolarization reserve of the heart. Since the 1990'ies it has been known that inhibition of K v 11.1 channels could lead to serious side effects arising from prolongation of the QT interval in the ECG [29] . The K v 11.1 channel can be characterized as pharmacologically promiscuous since, in addition to the class III anti-arrhythmics, a wide range of therapeutically unrelated drugs including antihistamines and antipsychotics block the channel [30] . Testing for K v 11.1 channel inhibition is implemented in drug discovery in many if not all pharmaceutical companies and this need for early stage in vitro safety screening, has been the single most significant driver for the development of automated patch clamp electrophysiology.
Activators of K v 11.1 constitute an entirely new opportunity for treating the long QT syndrome and has been suggested to be an effective new approach to control certain kinds of cardiac arrhythmias [31] . Positive modulators of K v 11.1 channels exerting different profiles have recently been described. RPR260243 slows deactivation and decrease inactivation kinetics [32] , NS3623 and NS1643 also decrease inactivation kinetics [33, 34] , whereas PD-11087 induces an uniform increase in currents in all states [35] . Although the site(s) for the activators has not been definitively settled, non-inactivating K v 11.1 mutants are generally insensitive towards the effects of the activators and mutagenesis studies have recently revealed distinct molecular determinants for the gating effects of RPR260243 [36] .
The unusual and specific voltage-dependency of the K v 11.1 channel is suited for effective cardiac repolarization, without much K + loss at the plateau phase. In order to avoid repolarization during the plateau phase, clinically useful positive modulators of K v 11.1 should preferentially, if not exclusively, affect the deactivation kinetics. Therefore, even though K v 11.1 channels may be an excellent molecular target for the development of new anti arrhythmic drugs, it is only so in the context of a very specific MOA of the active substance. Since these subtle effects cannot be revealed neither by binding nor by fluorescence based assays, the search for positive modulators of K v 11.1 channels represent an excellent example of the need for high-content primary electrophysiological screening.
Primary Screening for K v 11.1 Activators
We decided to commence on a screening for positive K v 11.1 modulators with our QPatch HT platform. We used the K v 11.1 expressing HEK293 cell line, which has been used for safety studies at NeuroSearch during the last 7 years and from which we therefore have a comprehensive reference data base concerning both basic electrophysiology and drug effects. The basic validation on QPatch revealed that the cells entering the whole-cell configuration, tended to fall into two categories; those that were fragile and lost within minutes (before compound additions) and those that lasted until the limit of the QPlate waste reservoir were reached after 12 compound additions. Furthermore, control experiments showed essentially identical electrophysiological behavior of the K v 11.1 channel recorded in the QPatch system compared to the manual patch clamp.
We settled on the final screening paradigm after a couple of validation rounds with designed compound plates containing known active (blockers and activators) and inactive substances. Different compounds were added sequentially to the same cell with 3 wash periods separating each addition. Furthermore, each compound was tested in quadruplicates, with the experimental software ensuring that individual compounds were applied to different cells, and that the order of additions were randomized with respect to time after establishment of the whole-cell configuration. The quadruplicate test paradigm was chosen to avoid that prior addition of a high-affinity K v 11.1 blocker (low off-rate) would mask the effect of the subsequent testing of a possible activator on the same cell. This scenario increased the likelihood of having all compounds tested at least once embraced by inactive compounds. Furthermore, as a running test for pharmacological sensitivity during the screening, a reference K v 11.1 blocker (verapamil) and a reference activator (proprietary NeuroSearch compound) were included on each compound plate. The vast number of compounds and the desire for n 4 meant that the number of experiments by far exceeded what can be manually evaluated. Consequently, careful assessment of each experiment was not practical and a swap onto increasingly relying on systematic filtering opportunities offered by the QPatch software was adopted although this paradigm shift was not followed rigorously. Fig. (7C) with the Cmpd A giving 31% increase and verapamil 44% decrease in the tail current. The chosen test concentrations for Cmpd A and verapamil were close to their EC 50 /IC 50 values (data not shown) and the average effects were thus as expected. However, inspection of Fig. (7B) reveals drop-outs for both verapamil and Cmpd A, which is sometimes registered as a blocker. We were not able to pinpoint whether the causes of these irregularities were human, technical or biological in nature. However, the data illustrate the value of testing positive controls blindly at least at the beginning of a screening campaign. In the continuation, we focus on increasing the stability of the assay further. Fig. (8) shows an example of recordings obtained from a single cell during the screening campaign with the current traces obtained with two hits, Cmpd 7 and NS3623 (denoted Cmpd 10) shown in (A) and a plot of, mentioned from the top, the peak tail current, the steady-state current and the leak current versus time in (B). Despite a clear tendency towards a specific run-down of the K v 11.1 currents over time observed in the long lasting experiments, K v 11.1 retained its electrophysiological characteristics (Fig. 8A) and pharmacological sensitivity for more than 2 h. Clearly, the chosen screening scenario also allows the identification of different MOAs, e.g., Cmpd 7 more pronouncedly affects tail current amplitude than sustained current. Furthermore, reversibility of both compounds was immediately appreciated.
The overall success rate for this particular screening campaign was app. 43% of the trials ending with a wholecell recording. Fig. (9) shows an analysis of the different stages of progress: More than 90% of sites were successfully primed with intracellular and extracellular liquid with the resistance of the prepared chip of 2 M . n 79% of all cases a cell was positioned successfully on the chip and in 58% the primary seal criterion (100 M ) was reached. 32% of the 48 sites were genuine giga-seals and finally 43% possible sites were whole-cells. Note that even cells having lower seal resistances often entered into the whole-cell configuration, and although there was a tendency towards a correlation between high giga-seal values and quality/duration of the subsequent experiment, this was not absolute and did not warrant the exclusion of lower resistance seals. Overall, an average of 137 compounds was tested per QPlate amounting to a de facto throughput of approximately 700 compounds tested per day when repetitions are included. Fig. (7) . Validation of QPatch HT screen with activator as well as inhibitor of hK v 11.1 current. Cells were cultured and suspended as described in Fig. (1) but two T175 flasks were harvested with detachin that decreases HEK cells tendency to aggregate compared to trypsin treated cells. Extracellular saline was constituted as (in mM): 145 NaCl, 4 KCl, 2 CaCl 2 , 1 MgCl 2 and 10 HEPES, pH 7.4 with NaOH. 20 mM sucrose was added to raise the osmolarity to app. 310 mOsm. The IS was: 120 KCl, 10 EGTA, 1.75 MgCl 2 , 5.374 CaCl 2 and 10 HEPES, pH 7.2 with HCl. Also, 10 mM glucose was added to the extracellular and 4 mM ATP was added to the IS. After whole-cell configuration was established the voltage protocol was elicited every 10 s; from a holding potential of -80 mV a short step of 20 ms at -50 mV made offline leak subtraction possible. Activation of the channel was done by the subsequent step to +20 mV for 2 s followed by a step back to -50 mV to obtain the tail current that decayed until it was terminated after 2 s by stepping back to the holding potential. The QPatch HT has enabled the screening of a compound library for positive modulators of K v 11.1 channels. Despite some as yet unexplained irregularities in the initial data set, the technology is promising and superior to the possibilities offered by manual patch clamp as well as traditional HTS techniques. Fig (7) . Compounds were prepared in 96-well format in plates with glass inserts. 250 l of 10 M test compound was diluted from 10 mM stock in extracellular saline prepared freshly. The compound plate was covered with Scotch tape to prevent evaporation and identified with unique barcode for compound identification. Diluted compounds were used for up to 3 days while at room temperature. (A) The effect of two compounds tested in 30 M. The scale has been altered in order to align the control traces from the two examples. The two compounds exhibit different profiles in that Cmpd 7 predominantly increased the tail without much effect on the steady state current whereas Cmpd 10 had more equal effects on steady state and tail currents. (B) The entire IT-plot from a whole-cell receiving 12 compound additions with peak tail current ( ), steadystate current ( ) and leak currents ( ). Each compound period is indicated by the bar above the plot and is preceded by 3 additions of saline to ensure satisfactory washing out of compound. The traces in (A) are taken from (B) and Cmpd 10 is the published K v 11.1 activator NS3623. First the QPlate is primed with intra-and extracellular solutions and the resistance on the primed plate is evaluated ( 2 M ), which was reached in 90% of the cases. Next cells prepared by the QPatch in a final density of 6•10 6 /mL is added to the plate and a successful positioning means that the initial chip resistance has raised more than 750%. This was achieved with a rate of 79%. Seal achievement is set by the operator, in this case 100 M , whereas Giga-seal is the fraction of 1 G or better seals and these were reached with 58% and 32% respectively. Finally the whole-cell configuration is established and detected by the appearance of capacitance spikes with an overall rate of 43%.
NeuroSearch proprietary Cmpd A, used as positive modulator of K v 11.1 channels gave some "drop-outs" in its effects as shown in Fig. (7) . It is now evident to us that Cmpd A is very unstable at room temperature and breaks down in few days. Furthermore, the decomposed substance has been found to block K v 11.1 channels and this is the most likely explanation for the drop-outs during the screening campaign described herein. In the remaining screening we have only used Compd A prepared from dry compound on the same day.
CONCLUSIONS
Ion channel pharmacology is complicated and spans a wide range of mechanisms related to both ion permeation and gating processes. Often the most useful drugs are not the most potent binders, but the compounds having a distinct modulatory MOA allowing a slightly changed ion channel response towards pathophysiological or even normal physiological stimuli.
Automated planar chip electrophysiology represents a hitherto unprecedented possibility for the design of dedicated high-information content screening programs for the detection of ion channel modulators. In the present paper, we have selected three case stories, where the technology, represented by the QPatch system, has been evaluated for the detection of substances with a predefined, mandatory mode of action, namely state-dependent Na v -inhibitors, positive and negative modulators of K Ca 2.3 channels, and positive modulators of K v 11.1 channels. For all three channel types, that each represents particular experimental challenges, the QPatch offers experimental flexibility and yield data quality that compares with the ones obtainable with traditional whole cell patch clamp. Furthermore, the system has consistently provided stable detection of compounds with the required MOAs.
We conclude, that planar electrophysiology is a valuable technology in lead optimization-and secondary screening programs. In some cases, compounds with the desired MOA may be undetectable due to limited resolution and experimental control of traditional HTS methods. In such cases planar electrode electrophysiology, as the QPatch HT or the IonWorks HT (or for special applications, requiring intracellular saline exchange, the Port-a-Patch system), may become the technology of choice, even for primary screening campaigns. This may become yet more realistic with further increases in capacity and lowered price of the disposable parts of these systems.
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